至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Independent anti-angiogenic capacities of coagulation factors X and Xa

J Cell Physiol. 2015; 
Lange S, Gonzalez I, Pinto MP, Arce M, Valenzuela R, Aranda E, Elliot M, Alvarez M, Henriquez S, Velasquez EV, Orge F, Oliva B, Gonzalez P, Villalon M, Cautivo KM, Kalergis AM, Pereira K, Mendoza C, Saez C, Kato S, Cuello MA, Parborell F, Irusta G, Palma V, Allende ML, Owen GI.
Products/Services Used Details Operation
Peptide Synthesis … RX and H were applied 30 min prior to treatment with coagulation factors. Matrigel was purchased from Becton‐Dickinson (San Diego, CA). Activating and blocking peptides for PAR‐1, PAR‐2 were obtained from Genscript (Piscataway, NJ) … Get A Quote

摘要

Knockout models have shown that the coagulation system has a role in vascular development and angiogenesis. Herein, we report for the first time that zymogen FX and its active form (FXa) possess anti-angiogenic properties. Both the recombinant FX and FXa inhibit angiogenesis in vitro using endothelial EA.hy926 and human umbilical cord vascular endothelial cells (HUVEC). This effect is dependent on the Gla domain of FX. We demonstrate that FX and FXa use different mechanisms: the use of Rivaroxaban (RX) a specific inhibitor of FXa attenuated its anti-angiogenic properties but did not modify the anti-angiogenic effect of FX. Furthermore, only the anti-angiogenic activity of FXa is PAR-1dependent. Using in vivo mo... More

关键词